Materials and Methods
We compared QFT-GIT results at baseline and after 6 months of daily IPT (isoniazid 5 mg/kg/d; maximum, 300 mg/d) or 6 months of observation in healthy adults with positive TST results enrolled in a phase 1 randomized clinical trial to assess the safety and immunogenicity of BCG revaccination after IPT or observation. Healthy adults aged 18 to 40 years with HIV-seronegative test results, a BCG scar, and a TST Ն 15 mm induration at 48 to 72 h after placement (2 tuberculin units purifi ed protein derivative [PPD] [PPD-RT23; Statens Serum Institut]) were randomly assigned to receive either IPT (180 doses within no more than 7 months) or observation for an equivalent time period before BCG revaccination. TST was performed by trained personnel following standard procedures, including intradermal injection of PPD-RT23 into the volar aspect of the left forearm and measurement of the transverse diameter of induration 48 to 72 h after injection. Subjects assigned to the observation before BCG revaccination group subsequently received IPT beginning 6 months after revaccination. IPT administration was supervised by trained study fi eld workers.
Adherence to IPT was monitored by treatment supervisors and study staff. The number of INH tablets was reconciled and a 1-month supply dispensed at scheduled monthly clinic visits during IPT. Treatment cards were issued to subjects, with daily entries for medication taken initialed and dated by the subject and his or her treatment supervisor. Treatment supervisors were nominated by subjects and were most often responsible members of their household. Supervisors were trained by study fi eld staff. At the monthly clinic visits during IPT, study staff reviewed the treatment card and reconciled counts of returned empty and unopened study medication containers. Missed doses and other discrepancies were noted and discussed with the subject. As a further measure to monitor adherence, INH metabolite testing (BBL Taxo INH test strips; BD) was done on urine samples provided by the subject during scheduled visits at months 1, 3, and 5 of IPT and on two unscheduled spot urine samples collected by fi eld workers at home visits during the fi rst and second 3 months of IPT. Eighty-seven percent of all urine INH metabolite tests performed during the study were positive results.
Healthy volunteers from the Worcester area near Cape Town, South Africa, were recruited for the parent trial. This rural town (population, 92,000) has a smear-positive TB incidence of 815 per 100,000 population per year and an all-forms TB incidence of 1,030 per 100,000 population per year (Regional Health Department, unpublished data, Western Cape Province, South Africa, 2010). In an earlier study, 52% of healthy adults without HIV in this area had a positive TST result Ն 15 mm . 21 Active TB in all subjects was excluded at baseline by history and physical examination, posteroanterior chest radiography, sputum smear and culture, and other testing if indicated.
QFT-GIT, an in vitro T-cell IGRA using the mycobacterial antigens early secreted antigenic target (ESAT)-6, culture filtrate protein (CFP)-10, and TB 7.7(p4), was done according to the manufacturer's instructions 22 for each subject at baseline, after completion of IPT or observation, and after BCG revaccination. Testing was completed at the quality-controlled, Good Laboratory Practice-certified laboratory of the South African Tuberculosis Vaccine Initiative, Cape Town, South Africa. Laboratory staff performing QFT-GIT assays were blinded to each subject's group (IPT or observation). QFT-GIT data were analyzed with the manufacturer's software-generated standard curves, pass-fail criteria, and defi nitions. Test results were determined positive (IFN-g for TB antigens minus negative control Ն 0.35 IU/mL), negative, or indeterminate (qualitative test result) and presented as the IFN-g concentration in International Units per milliliter (quantitative result). No indeterminate values were observed for any subject. QFT-GIT conversion was defi ned as a change from a negative hence, may be a marker of response to treatment. 4, 5 Several studies have reported decreases in MTBspecifi c T-cell response and MTB bacillary load during anti-TB treatment 4 or treatment of LTBI 6 ; however, the results have been inconsistent. Some studies showed a decline in interferon-g (IFN-g ) levels after treatment, whereas others showed no change or increased levels of IFN-g . 5, [7] [8] [9] [10] [11] More limited data are available on T-cell response and IGRA after treatment of LTBI, although there is substantial interest in identifying a biomarker of response to treatment of LTBI.
We recently completed a phase 1 randomized clinical trial in healthy South African adults with positive TST and HIV-seronegative results to study whether isonicotinylhydrazine (INH) treatment of LTBI before revaccination with BCG changed the magnitude of MTB-specifi c immune responses. Prior MTB infection may prevent optimal immune responses to live TB vaccines by inhibiting macrophage function, 12 preventing phagolysosomal fusion, [13] [14] [15] [16] and decreasing major histocompatibility complex class I and II presentation to T cells. [17] [18] [19] Preclearance of latent tubercle bacilli by isoniazid preventive therapy (IPT) might result in a better immunologic response following revaccination with BCG or a new TB vaccine. 20 Healthy volunteers with HIV-seronegative tests were randomly assigned to receive 6 months of either isoniazid for treatment of LTBI or observation before BCG revaccination. Active TB was excluded before enrollment. IGRA (QFT-GIT) was done at baseline, after completion of 6 months of IPT or observation, and after BCG revaccination. The aim of this substudy was to examine QFT-GIT responses before and after IPT in healthy patients with positive TST results living in a high TB incidence area to assess whether QFT-GIT is a useful biomarker of response to treatment of LTBI. rank test P 5 .03). The rate of decrease in IFN-g responses over time did not differ between the groups (Mann-Whitney-Wilcoxon test P 5 .31).
Qualitative QFT-GIT Results
At baseline, 36 of 39 subjects (92%) who received IPT and 37 of 39 subjects (95%) who were observed had positive QFT-GIT results. QFT-GIT results reverted from positive to negative in two subjects (5%) in the IPT group and in two subjects (5%) in the observation group. Five subjects had negative QFT-GIT results at baseline, which remained negative. There were no signifi cant differences (Fisher exact test P 5 1.0) between the groups with respect to baseline positivity or the proportion of subjects whose results reverted to negative.
Discussion
To our knowledge, there currently are no wellqualifi ed or validated biomarkers of response to TB treatment or treatment of LTBI. Earlier studies suggested that IGRA results may correlate with MTB bacillary load and might be a potential surrogate marker of response to therapy. Several studies have shown decreases in IGRA or reversion to negative results after treatment of active TB 5, 23 or LTBI. 6, 11 Most of these reports are from small cohorts and lacked proper controls. In the present substudy from a randomized clinical trial of adults with positive TST results from a high TB incidence setting and randomly allocated to either IPT or observation before BCG revaccination, we found no differences in decline in QFT-GIT or reversion to negative results after IPT or observation alone. The results in this South African population confi rm those from a recent randomized placebo-controlled trial in household contacts of patients with TB in the Gambia, which examined whether an IFN-g enzymelinked immunospot (ELISPOT) assay using ESAT-6 and CFP-10 antigens was a useful biomarker of treatment effi cacy in LTBI. 24 In the Gambia trial, which also enrolled subjects with positive TST results (median, 15.5 mm induration), the proportion of subjects with a positive ELISPOT assay and the number of median spot-forming units decreased over time during IPT and follow-up but did not differ between those treated with IPT and those receiving placebo.
Earlier uncontrolled studies reported that results in 8% to 25% of subjects receiving 6 months of INH for the treatment of LTBI reverted to negative. [25] [26] [27] The similar results of the present study in South Africa and the recent trial in the Gambia of two different IGRAs [QFT-GIT using an IFN-g enzyme-linked immu nosorbent assay using ESAT-6, CFP-10, and TB 7.7(p4) antigens and an IFN-g ELISPOT assay using ESAT-6 and CFP-10 antigens, respectively] IFN-g result ( , 0.35 IU/mL) to a positive result. QFT-GIT reversion was defi ned as a change from a positive ( Ն 0.35 IU/mL) to a negative ( , 0.35 IU/mL) result. 11 Because QFT-GIT cannot accurately measure IFN-g concentrations . 10 IU/mL, IFN-g levels . 10 IU/mL were assigned a value of 10 IU/mL for analysis. 11, 22 QFT-GIT responses before and after IPT or observation were the focus of the present analysis. QFT-GIT response after BCG revaccination was a secondary immunogenicity end point for the parent trial and will be reported separately.
The study was conducted in accordance with the amended Declaration of Helsinki. The trial protocol was approved by the Medicines Control Council of South Africa, the Human Research Ethics Committee of the University of Cape Town (387/2008), and the University Hospitals Case Medical Center institutional review board. Written informed consent was obtained from all subjects.
Mann-Whitney-Wilcoxon and t tests were used for betweengroup comparisons of mean ranks and mean IFN-g values, respectively. The Wilcoxon signed rank test was used to assess signifi cant changes in paired IFN-g levels over time. Group proportions were compared by Fisher exact test. A two-tailed P , .05 was considered signifi cant. Analyses were done with SAS 9.3 (SAS Institute Inc) statistical software.
Results

Study Population
Of 253 subjects screened for the parent phase 1 clini cal trial, 85 were eligible, of whom 82 were assigned to IPT or observation before BCG revaccination by central, permuted block randomization after review of all screening data. Forty-two subjects were assigned to the IPT arm and 40 to the observation arm. Four subjects (three in the IPT group and one in the observation group) without a follow-up QTF-GIT test were excluded, leaving 39 subjects in each arm of the analysis.
Baseline clinical and sociodemographic characteristics are shown in Table 1 . Seventy percent of the subjects were women. The median age was 26.6 years. The median baseline TST induration was 19 mm. No signifi cant differences in baseline characteristics were observed between study groups. Active TB did not develop in any subject during the 22.5 months of scheduled study follow-up. Adherence to treatment was satisfactory. Ninety percent of subjects in the IPT group received 180 doses of INH within the parent trial protocol-specifi ed 7-month period. Four subjects (10%) received , 6 months of IPT (range, 61-106 days). The baseline QFT-GIT blood draw was done within a median of 9 days (interquartile range, 8-11 days; range, 6-59 days) after the TST was placed.
Quantitative QFT-GIT Results
The median baseline QFT-GIT result was 10 IU/mL. As shown in Figure 1 and Table 1 , IFN-g levels declined between baseline and the end of IPT (Wilcoxon signed rank test P Յ .0001) and observation (Wilcoxon signed more, assigning arbitrary diagnostic cutoffs is not fully consistent with the diagnostic spectrum of TB disease, latent infection, and clearance, 33 especially because QFT-GIT conversion and reversion rates did not differ between the two groups. Diluting plasma samples to be within the linear range of QFT-GIT is complex owing to the diffi culty of estimating appropriate dilution factors without a prior knowledge of the range of concentrations. Importantly, IFN-g release does not distinguish between active infection and cleared infection because antigen-specifi c memory T cells induced by prior exposure to MTB may persist. 34 These factors collectively provide evidence that IGRA performs poorly as a biomarker of infection clearance following IPT.
The persistently elevated IFN-g responses seen in the present subjects may be due to persistent infection with latent bacilli or to reinfection with ongoing stimulation and chronic activation of effector T cells producing IFN-g . IFN-g responses might decline in settings with less TB transmission and little reinfection during or following IPT. We repeated QFT-GIT shortly after completion of IPT; hence, it is possible that IFN-g responses may not have returned to normal at this time. 26 Repeating the test at additional time points to better characterize the kinetics of the response might be informative. 35 Exposure to environmental mycobacteria might also contribute to persistent IFN-g responses to some mycobacterial antigens. The antigens used in the QFT-GIT assay [ESAT-6, CFP-10, and TB 7.7(p4)] were selected because they are more specifi c to MTB than PPD and are not shared by BCG vaccine strains and most nontuberculous mycobacteria. Other strengths of the study are the use of standardized procedures for TST and QFT-GIT testing, careful exclusion of active TB at baseline, and administration of IPT and careful follow-up in a clinical trial setting.
Active TB did not develop in any of the subjects during follow-up, and we cannot comment on QFT-GIT responses and protective effi cacy against the development of TB. Additional studies with later IGRA and randomly allocated control groups in comparable high TB incidence settings cast further doubt on the utility of IGRAs as biomarkers of response to treatment of LTBI.
The present study has several limitations. The parent clinical trial enrolled subjects with TST Ն 15 mm to increase the likelihood that they were truly latently infected with MTB. We performed baseline QFT-GIT testing at a median of 9 days after TST. Some studies have reported increased positive IFN-g responses after TST, 28,29 whereas others have not. 30, 31 Leyten and colleagues 32 reported no evidence of a boosting of QFT-GIT responses in subjects undergoing TST 3 days before IGRA. Although we cannot exclude the possibility that baseline QFT-GIT responses were boosted by TST, any such effect would have applied equally to subjects receiving IPT or observation alone. We assigned a value of 10 IU/mL to IFN-g concentrations exceeding 10 IU/mL because assay standards lose linearity and predictive value outside this range. 11, 22, 32 Performing the same analysis with original values or a subset of values within this range yielded trends similar to what is reported in the present study. Further- measurements to better characterize the kinetics of IFN-g responses after treatment of LTBI and longterm follow-up for protection of TB in high and low TB transmission settings will be required to answer these questions.
In conclusion, biomarkers of response to treatment of LTBI and protection against the development of active TB would be valuable for TB control programs, infection control services, and clinical trialists. The present results and those of other prospective studies in high-TB-burden settings suggest that in vitro IGRAs to mycobacterial antigens are unlikely to be useful for this purpose.
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